IN
INCR
Intercure Ltd.
$0.8550
+0.59%
$46.5M
No data for this timeframe.
Vol
Market Cap$46.5M
Cap SizeNano Cap
SEC Reports2
Recent Activity
Apr 30, 2026
SEC
InterCure reported FY2025 revenue of NIS 270M (+13% YoY), a net loss of NIS 37M (improved from NIS 73M loss in 2024), an
PRESS-RELEASE — Impact 6/10
Apr 30, 2026
earnings
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
<p align="center"><i>The Company reported over NIS 270 million in revenue, NIS 37 million in Net los
Apr 30, 2026
SEC
InterCure's FY2025 20-F shows a 13% revenue increase to NIS 270M, driven by resumed Southern Facility production and fir
20-F — Impact 7/10
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Latest Reports
MIXED
PRESS-RELEASE
6/10
InterCure reported FY2025 revenue of NIS 270M (+13% YoY), a net loss of NIS 37M (improved from NIS 73M loss in 2024), an
Apr 30, 2026
BEARISH
20-F
7/10
InterCure's FY2025 20-F shows a 13% revenue increase to NIS 270M, driven by resumed Southern Facility production and fir
Apr 30, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 1 mixed, 0 neutral. Avg impact: 6.5/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2025-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 30, 2026
earnings
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
<p align="center"><i>The Company reported over NIS 270 million in revenue, NIS 37 million in Net loss, NIS 47 million in Adjusted EBITDA and NIS 17 mi
Mar 3, 2026
other
InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement
<p align="justify"><b>NEW YORK and HERZLIYA, Israel, March 03, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. </b>(Nasdaq: INCR) (TASE: INCR) (“<b>InterCur